LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy - Quiz - MDSpire

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy

  • By

  • Juan Zhang

  • Mingzhen Zhou

  • Ziyue Jin

  • Wenyan Cao

  • Xuena Zhang

  • Fanlai Meng

  • Haiyan Wei

  • Jie Shen

  • July 1, 2026

  • 0 min

Share

Original Source(s)

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy

  • by Juan Zhang, Mingzhen Zhou, Ziyue Jin, Wenyan Cao, Xuena Zhang, Fanlai Meng, Haiyan Wei, Jie Shen

  • July 1, 2026

Related Content

Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer

The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes

Efficacy and safety of transoral endoscopic thyroidectomy vestibular approach of papillary thyroid carcinoma: a network meta-analysis